Semaglutide, the active ingredient in diabetes drug Ozempic, could reduce the risk of heart failure events by 27 per cent and the risk of cardiovascular death by 29 per cent in people with diabetes and chronic kidney disease, a study has found.

Scientists don’t yet know why. But the findings, taken from a new study of a previous clinical trial called the FLOW trial, are important because heart disease is the leading cause of death in Australia and elsewhere.